Actavis Leads the Way

NEW YORK (TheStreet) -- Some financial people do not really look at all the good things drug companies do. Instead, they focus on the creative destruction that happens when new replaces the old.

Think of all the popular brand names of the last decade: Rogaine, Plavix, Cymbalta, Oxycontin, Celebrex. It's a long list of exclusive money-making home runs now generic also-rans starring with a different label at a pharmacy shelf near you.

While lots of analysts like to pay attention to the pipelines full of miracle drugs of tomorrow, some companies do quite well with the miracle drugs of yesterday -- the generics.

Let's look at one: Actavis (ACT).

The past 15 months have been a dog fight for supremacy among three sectors: pharmaceutical, biotech and Internet. At the start of the new year, pharmaceuticals emerged at the top of my leader board.

Data from Best Stocks Now App

One pharmaceutical that has performed and continues to perform quite well is Actavis. It has been a Gunderson Best Stock Now for quite some time and continues to be.

Data from Best Stocks Now App

Headquartered in New Jersey, ACT is a $31 billion large-cap company that develops, manufactures and distributes generic and branded drugs for hypertension, elevated cholesterol, contraception and pain. It is  currently working on a generic NuvaRing, a contraceptive.

If you liked this article you might like

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

What Bill Ackman's Voice Could Mean for the Valeant Board Room

What Bill Ackman's Voice Could Mean for the Valeant Board Room

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?